SecSonar.com

Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Neurocrine Biosciences, Inc. (NBIX) is a Biotechnology company based in US with a market capitalization of $15.9B. Revenue grew 21.4% year-over-year and the company generated $748.7M in free cash flow. This page tracks NBIX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 1.8K employees · IPO May 23, 1996

Valuation

Valuation & price

$158.42 · as of May 17, 2026 · -9.1% vs 52w high

33.9

P/E ratio

Latest-FY diluted EPS

4.90

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$174$149$124Jul 25Dec 25Jul 26Jul 7, 25$127.88Jul 9, 25$133.51Jul 11, 25$133.46Jul 15, 25$131.24Jul 17, 25$134.11Jul 21, 25$131.83Jul 23, 25$133.66Jul 25, 25$132.14Jul 29, 25$134.19Jul 31, 25$128.23Aug 4, 25$128.04Aug 6, 25$128.43Aug 11, 25$123.98Aug 13, 25$131.62Aug 15, 25$132.90Aug 19, 25$132.81Aug 21, 25$135.28Aug 25, 25$133.99Aug 27, 25$138.13Aug 29, 25$139.60Sep 3, 25$136.11Sep 5, 25$144.10Sep 9, 25$144.17Sep 11, 25$143.60Sep 16, 25$140.90Sep 18, 25$145.66Sep 22, 25$146.62Sep 24, 25$146.67Sep 26, 25$142.00Sep 30, 25$140.38Oct 2, 25$136.74Oct 6, 25$139.43Oct 8, 25$139.08Oct 10, 25$136.63Oct 14, 25$137.23Oct 16, 25$137.52Oct 21, 25$142.65Oct 23, 25$143.67Oct 27, 25$148.94Oct 29, 25$138.02Oct 31, 25$143.21Nov 4, 25$143.19Nov 6, 25$154.80Nov 10, 25$150.02Nov 12, 25$146.85Nov 14, 25$144.86Nov 18, 25$138.63Nov 20, 25$138.98Nov 25, 25$143.53Nov 28, 25$152.16Dec 2, 25$152.48Dec 4, 25$154.22Dec 8, 25$154.99Dec 10, 25$155.63Dec 12, 25$152.80Dec 16, 25$148.74Dec 18, 25$141.84Dec 22, 25$147.53Dec 24, 25$146.93Dec 29, 25$143.64Jan 2, 26$140.60Jan 6, 26$137.35Jan 8, 26$135.57Jan 12, 26$132.66Jan 14, 26$135.33Jan 16, 26$132.39Jan 21, 26$135.41Jan 23, 26$136.18Jan 27, 26$133.89Jan 29, 26$137.96Feb 2, 26$137.63Feb 4, 26$137.86Feb 9, 26$139.56Feb 11, 26$137.44Feb 13, 26$124.12Feb 18, 26$128.38Feb 20, 26$128.63Feb 24, 26$130.96Feb 26, 26$130.64Mar 2, 26$132.38Mar 4, 26$133.44Mar 6, 26$128.13Mar 10, 26$129.86Mar 12, 26$127.78Mar 17, 26$130.71Mar 19, 26$129.70Mar 23, 26$127.05Mar 25, 26$131.13Mar 27, 26$128.32Mar 31, 26$131.74Apr 2, 26$131.60Apr 7, 26$130.90Apr 9, 26$131.64Apr 13, 26$126.32Apr 15, 26$131.44Apr 17, 26$133.25Apr 22, 26$131.18Apr 24, 26$127.68Apr 28, 26$128.12Apr 30, 26$131.67May 4, 26$134.07May 6, 26$147.02May 8, 26$152.25May 12, 26$155.80May 14, 26$159.05May 18, 26$157.21May 20, 26$154.67May 22, 26$156.70May 28, 26$156.39Jun 1, 26$161.00Jun 3, 26$165.11Jun 5, 26$163.88Jun 9, 26$165.24Jun 11, 26$162.71Jun 15, 26$159.51Jun 17, 26$159.00Jun 22, 26$161.62Jun 24, 26$166.06Jun 26, 26$168.52Jul 2, 26$174.26
$123.1052-week range$174.26
Loading valuation history…

Fundamentals

Key fundamentals

$15.9B

Market cap

21.4%

Revenue growth (YoY)

98.2%

Gross margin

$748.7M

Free cash flow (USD)

-$1.1B

Net debt

Net cash position

-0.9%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$15.0MFY 2017$161.6MFY 2018$451.2MFY 2019$788.1MFY 2020$1.0BFY 2021$1.1BFY 2022$1.5BFY 2023$1.9BFY 2024$2.4BFY 2025$2.9B
$15M$2.9B

Free cash flow by year

2016 → 2025

FY 2016$-110.3MFY 2017$-101.3MFY 2018$76.6MFY 2019$132.3MFY 2020$217.6MFY 2021$233.1MFY 2022$322.9MFY 2023$361.6MFY 2024$557.2MFY 2025$748.7M
-$110.3M$748.7M

Gross margin by year

2021 → 2025

FY 202198.7%FY 202298.4%FY 202397.9%FY 202498.6%FY 202598.2%
98.7%98.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

11

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $1.7M · 10b5-1 PlanLippoldt Darin · Chief Legal Officer · $1.7MJun 30, 2026Filing
  • Insider sellInsider Sell $4.1M · 10b5-1 PlanSHERWIN STEPHEN A · Director · $4.1MJun 9, 2026Filing
  • Insider sellInsider Sell $210K · 10b5-1 PlanNorwalk Leslie V · Director · $210.1KJun 8, 2026Filing
  • Insider sellInsider Sell $5.8M · 10b5-1 PlanCooke Julie · Chief Human Resources Officer · $5.8MJun 4, 2026Filing
  • Insider sellInsider Sell $354K · 10b5-1 PlanDelaet Ingrid · Chief Regulatory Officer · $354.3KJun 2, 2026Filing
  • Insider sellInsider Sell $1.8M · 10b5-1 PlanOnyia Jude · Chief Scientific Officer · $1.8MJun 2, 2026Filing
  • Insider sellInsider Sell $1.7M · 10b5-1 PlanOnyia Jude · Chief Scientific Officer · $1.7MMay 29, 2026Filing
  • Insider sellInsider Sell $609K · 10b5-1 PlanBoyer David W. · Chief Corp. Affairs Officer · $609KMay 28, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 28, 2026Filing
  • Insider sellInsider Sell $37.8M · 10b5-1 PlanGORMAN KEVIN CHARLES · Director · $37.8MMay 21, 2026Filing

Questions

Frequently asked questions

What is Neurocrine Biosciences, Inc.'s market cap?

Neurocrine Biosciences, Inc. (NBIX) has a market capitalization of $15.9B.

What is NBIX's P/E ratio?

NBIX trades at a price-to-earnings ratio of 33.9, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is NBIX's price-to-book (P/B) ratio?

NBIX trades at 4.90 times book value per share.

Are insiders buying NBIX stock?

SEC Form 4 filings show no open-market insider buys at Neurocrine Biosciences, Inc. in the last 90 days (11 sells).

Same arena

Related companies in Biotechnology

GMAB

Genmab A/S

$16.3B

JAZZ

Jazz Pharmaceuticals plc

$14.6B

ASND

Ascendis Pharma A/S

$13.7B

BBIO

BridgeBio Pharma, Inc.

$13.2B

EXEL

Exelixis, Inc.

$12.9B

IONS

Ionis Pharmaceuticals, Inc.

$12.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.